Samanta Debopam
Child Neurology Section, Department of Pediatrics, University of Arkansas for Medical Sciences, 1 Children's Way, Little Rock, AR 72202, USA.
Children (Basel). 2022 Aug 2;9(8):1159. doi: 10.3390/children9081159.
Despite the availability of more than 30 antiseizure medications (ASMs), the proportion of patients who remain refractory to ASMs remains static. Refractory seizures are almost universal in patients with epileptic encephalopathies. Since many of these patients are not candidates for curative surgery, there is always a need for newer ASMs with better efficacy and safety profile. Recently, the anti-obesity medication fenfluramine (FFA) has been successfully repurposed, and various regulatory agencies approved it for seizures associated with Dravet and Lennox-Gastaut syndromes. However, there is a limited in-depth critical review of FFA to facilitate its optimal use in a clinical context. This narrative review discusses and summarizes the antiseizure mechanism of action of FFA, clinical pharmacology, and clinical studies related to epilepsy, focusing on efficacy and adverse effects.
尽管有30多种抗癫痫药物（ASMs）可供使用，但对ASMs仍难治的患者比例保持不变。难治性癫痫发作在癫痫性脑病患者中几乎普遍存在。由于这些患者中的许多人不适合进行根治性手术，因此始终需要疗效和安全性更好的新型ASMs。最近，抗肥胖药物芬氟拉明（FFA）已成功实现重新利用，并且各种监管机构批准其用于与德雷维特综合征和伦诺克斯-加斯托综合征相关的癫痫发作。然而，关于FFA的深入批判性综述有限，难以促进其在临床环境中的最佳使用。本叙述性综述讨论并总结了FFA的抗癫痫作用机制、临床药理学以及与癫痫相关的临床研究，重点关注疗效和不良反应。
